Medical Technology

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 4 years ago

Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More

@xconomy.com 4 years ago

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

@xconomy.com 4 years ago

Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits

@xconomy.com 4 years ago

Review: Inside the House of Lies at Theranos

@xconomy.com 5 years ago

Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More

@xconomy.com 5 years ago

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

@xconomy.com 5 years ago

Shine Raises $30M, Could Add $150M More After Inking Deerfield Deal

@xconomy.com 5 years ago

After Deal Stalled, Shine Medical Eyeing Up to $160M from Deerfield

@xconomy.com 5 years ago

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

@xconomy.com 5 years ago

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

@xconomy.com 5 years ago

Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum